Zydus to Acquire Assertio for $166.4 Million

Published: 2026-05-13 08:34:04 ET ASRT

Published on 05/13/2026 at 08:34 am EDT

By Nicholas G. Miller

A subsidiary of Zydus Lifesciences agreed to acquire pharmaceutical company Assertio Holdings for $166.4 million, topping Assertio's previous sale agreement with Garda Therapeutics.

The Zydus offer of $23.50 a share in cash represents a 7.8% premium to the prior Garda agreement worth $21.80 a share and a 76% premium to Assertio's unaffected closing stock price on March 20.

The Assertio board determined that the Zydus offer is superior and authorized the company to terminate the agreement with Garda.

The Zydus offer "has no financing contingencies, requires no third-party financing, and is fully guaranteed by a creditworthy Zydus entity, providing Assertio with direct recourse in the event of a breach or failure to close," Assertio said.

The deal is expected to close in the second quarter.

Write to Nicholas G. Miller at [email protected].

(END) Dow Jones Newswires

05-13-26 0830ET